Evidence map›Paper›PMID 33543570›Full record

ArticleJournal of clinical hypertension (Greenwich, Conn.)2021

Blood pressure variability and target organ damage regression in hypertension.

Cesare Cuspidi, Stefano Carugo, Marijana Tadic

Open access · diamondAbstract read
In one paragraph

Article in Journal of clinical hypertension (Greenwich, Conn.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Assessment of blood pressure variability: characteristics and comparison of blood pressure measurement methods.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Blood pressure variability and target organ damage regression in hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Cesare CuspidiDepartment of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy.ORCID 0000-0002-7689-478X
Stefano CarugoDepartment of Clinical Sciences and Community Health, University of Milano and Fondazione IRCCS Policlinico di Milano, Italy.
Marijana TadicUniversity Clinical Hospital Centre "Dragisa Misovic", Belgrade, Serbia.ORCID 0000-0002-6235-5152
IRCCS Istituto Auxologico Italiano · ITUniversity Hospital Center Dr Dragiša Mišović · RSUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study by Triantafyllidi et al. supports the view that regression of subclinical cardiac damage requires an effective 24-hour blood pressure (BP) control along with a reduction in BP variability and suggests that the assessment of BPV and its modifications during the course of therapy may be an useful approach in predicting the beneficial effects of treatment on cardiac structure. However, some aspects and limitations of this study require caution in drawing firm conclusions. So, further investigation is needed to determine if reduction of BPV is actually associated with a regression in cardiac and extracardiac organ damage to identify which which classes of antihypertensive drugs are most effective in reducing BPV, and to elucidate whether those treatments provide additional clinical benefit, independent of the conventional BP targets.

Indexed as

HypertensionAntihypertensive AgentsBlood PressureHeartHumansAntihypertensive Agentsblood pressure controlblood pressure variabilityorgan damage

Identifiers

PMID33543570
PMCPMC8678798
OpenAlexW3126481220

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.